source
- Novartis' del-desiran fails primary endpoint in phase 3 Harbor trial for myotonic dystrophy type 1Novartis announced that its experimental therapy del-desiran did not meet the primary endpoint in the phase 3 Harbor trial, which evaluated improvement in video hand opening time in patients with m…
- Democrats outline health-care priorities as they aim to retake House before November midtermsThe article notes that Democrats are sharpening their health‑care proposals as the November midterm elections approach, signaling a more detailed agenda should they regain control of the House. Ho…